Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in
most squamous cell carcinomas of the head and neck (SCCHN); this overexpression is
associated with more aggressive disease and poorer prognosis. In the EU, cetuximab is
approved in combination with radiation therapy for the treatment of locally advanced
SCCHN and in combination with platinum-based chemotherapy for the treatment of …

Cetuximab (Erbitux®) is a human-mouse chimeric monoclonal antibody, which competitively
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR)
to inhibit dimerisation and, subsequently, inhibit tumour growth and metastasis. In the EU
and the US, cetuximab has been approved for use with concomitant radiotherapy in patients
with locally advanced squamous cell carcinoma of the head and neck (SCCHN) and in
combination with irinotecan for the treatment of metastatic colorectal cancer (mCRC) in …